Thermo Fisher Scientific (NYSE:TMO) Cut to “Hold” at Wall Street Zen

Wall Street Zen downgraded shares of Thermo Fisher Scientific (NYSE:TMO) from a buy rating to a hold rating in a research note released on Saturday,Wall Street Zen reports.

A number of other equities research analysts have also weighed in on TMO. KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Citigroup lowered Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a research note on Wednesday, September 9th. HSBC upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 1st. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a report on Monday, July 6th. Finally, Deutsche Bank Aktiengesellschaft lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, September 9th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $624.64.

Thermo Fisher Scientific Stock Performance

TMO opened at $614.11 on Friday. The company has a market cap of $227.07 billion, a P/E ratio of 33.03, a price-to-earnings-growth ratio of 2.55 and a beta of 0.85. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The firm’s 50-day moving average price is $582.32 and its 200-day moving average price is $519.25. Thermo Fisher Scientific has a 52-week low of $435.27 and a 52-week high of $647.00.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same period last year, the business earned $4.28 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts anticipate that Thermo Fisher Scientific will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 275 shares of the business’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $627.05, for a total value of $172,438.75. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $77,707,171.25. The trade was a 0.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president owned 14,784 shares of the company’s stock, valued at $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 73,768 shares of company stock valued at $44,122,820 in the last three months. 0.33% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank OZK purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $1,096,000. Ausdal Financial Partners Inc. acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth $456,000. North Dakota State Investment Board purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at $7,505,000. BlackRock Inc. purchased a new position in shares of Thermo Fisher Scientific during the second quarter worth about $15,501,867,000. Finally, German American Bancorp Inc. acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth about $4,920,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.